Given the crucial role of GLI1 in regulating sorafenib resistance, we evaluated the therapeutic effect of GANT61 treatment and its combined effect with sorafenib in vivo using PGC7-transfected HCC cells. Here, GLI1 is linked to hepatocellular carcinoma.